Fig. 7
From: Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
Synergistic effects of PD-L1 monoclonal antibody and MET inhibition in a subcutaneous mouse model. A Drug treatment protocol for capmatinib and PD-L1 antibody in C57/BL6 mice. At the endpoint, tumors were extracted and assessed via flow cytometry. B-E Sizes of subcutaneous KPC tumors in C57/BL6 mice treated with capmatinib and/or PD-L1 antibody. Mouse body weights (B), representative tumor images (C), tumor volumes (D), and tumor weights (E) are shown. F-G Quantification of CD3 + T cells (F) and CD8 + T cells (G) from purified tumor-infiltrating lymphocytes